The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
JAK2V617F mutation for the early diagnosis of Ph− myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis
Open accessAbstract
Recent studies suggested that JAK2V617F mutation is frequent in patients with splanchnic vein thrombosis (SVT) but not in patients with other venous thromboembolic events (VTE). However, whether screening for the JAK2V617F mutation in VTE patients is justified remains unclear. Therefore, we performed a systematic review to assess the frequency of JAK2 mutation in VTE patients and the role of JAK2V617F mutation in the diagnosis of myeloproliferative neoplasms. MEDLINE and EMBASE databases were searched. Two reviewers independently performed study selection and extracted study characteristics. Pooled odds ratios of case-control studies and weighted mean proportion of the prevalence of JAK2V617F mutation of uncontrolled series were calculated. Twenty-four studies involving 3123 patients were included. Mean prevalence of JAK2 mutation was 32.7% (95% confidence interval, 25.5%-35.9%) in SVT patients. JAK2 mutation was associated with increased risk of SVT (odds ratio, 53.98; 95% confidence interval, 13.10-222.45). Mean prevalence of JAK2 mutation in other VTE patients was low (range, 0.88%-2.57%). Presence of JAK2V617F mutation in SVT patients was associated with a subsequent diagnosis of myeloproliferative neoplasm in many patients. JAK2 mutation is strongly associated with SVT, and routine screening of JAK2 mutation appears to be indicated in these patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A meta-analysis reported a JAK2 mutationprevalenceof32.7%(95%CI25.5 e 35.9%)inpatients with AMVT compared with approximately 1% in patients with VTEinothersites, and found a strong association between JAK2 mutation and MVT (OR 53.9, 95% CI 13.1 e 222.5). 214”
In the citing paper
“A meta-analysis reported a JAK2 mutationprevalenceof32.7%(95%CI25.5 e 35.9%)inpatients with AMVT compared with approximately 1% in patients with VTEinothersites, and found a strong association between JAK2 mutation and MVT (OR 53.9, 95% CI 13.1 e 222.5). 214”
In the citing paper
“The JAK2 mutation is diagnostic of myeloproliferative diseases and appears to be linked to the development of AMVT.”
In the citing paper
“Moreover, 52% (95% CI 38 e 67%) of patients with MVT and JAK2 mutation were diagnosed with a myeloproliferative disease during follow up, with MVT being the first manifestation of the underlying condition. 214”
In the citing paper
“AMVT is a common first clinical manifestation in patients with newly diagnosed myeloproliferative diseases such as polycythemia vera or essential thrombocytosis.”
In the citing paper
“A meta-analysis reported a JAK2 mutationprevalenceof32.7%(95%CI25.5 e 35.9%)inpatients with AMVT compared with approximately 1% in patients with VTEinothersites, and found a strong association between JAK2 mutation and MVT (OR 53.9, 95% CI 13.1 e 222.5). 214”
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Meta-analysis of Observational Studies in Epidemiology<SUBTITLE>A Proposal for Reporting</SUBTITLE>
Stroup, D. F. (2000) · JAMA · doi:10.1001/jama.283.15.2008 · Cited by 20,623
Statistical Aspects of the Analysis of Data From Retrospective Studies of Disease
(1959) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/22.4.719 · Cited by 14,689
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
James, C., Ugo, V., Couedic, J. P. L., Staerk, J., Delhommeau, F., Lacout, C., Garçon, L., Raslová, H., Berger, R., Griscelli, A. B., et al. (2005) · Nature · doi:10.1038/nature03546 · Cited by 3,542
A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders
Kralovics, R., Passamonti, F., Buser, A. S., Teo, S.-S., Tiedt, R., Passweg, J. R., Tichelli, A., Cazzola, M., & Skoda, R. C. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051113 · Cited by 3,470
Investigating and dealing with publication and other biases in meta-analysis
Sterne, J. A. C., Egger, M., & Smith, G. D. (2001) · BMJ · doi:10.1136/bmj.323.7304.101 · Cited by 2,225
Tefferi, A., Thiele, J., Orazi, A., Kvasnicka, H., Barbui, T., Hanson, C., Barosi, G., Verstovsek, S., Birgegard, G., Mesa, R., et al. (2007) · Blood · doi:10.1182/blood-2007-04-083501 · Cited by 919
Campbell, P. J., Scott, L. M., Buck, G. A. N., Wheatley, K., East, C. L., Marsden, J. T., Duffy, A. M., Boyd, E. M., Bench, A. J., Scott, M. A., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67785-9 · Cited by 651
Polycythemia Vera: The Natural History of 1213 Patients Followed for 20 Years
Policitemia, G. I. S. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-123-9-199511010-00003 · Cited by 507
Cited by
Sorted by citations
Epidemiology of venous thromboembolism
Heit, J. A. (2015) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.83 · Cited by 1,277
The epidemiology of venous thromboembolism
Heit, J. A., Spencer, F. A., & White, R. H. R. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-015-1311-6 · Cited by 1,142
Editor's Choice – Management of the Diseases of Mesenteric Arteries and Veins
Björck, M., Koelemay, M., Acosta, S., Bastos Goncalves, F., Kölbel, T., Kolkman, J. J., Lees, T., Lefevre, J. H., Menyhei, G., Oderich, G., et al. (2017) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2017.01.010 · Cited by 658
Therapeutic strategies for thrombosis: new targets and approaches
Mackman, N., Bergmeier, W., Stouffer, G. A., & Weitz, J. I. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0061-0 · Cited by 413
Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis
Smalberg, J. H., Arends, L. R., Valla, D. C., Kiladjian, J., Janssen, H. L. A., & Leebeek, F. W. G. (2012) · Blood · doi:10.1182/blood-2011-09-376517 · Cited by 374
Metadata
- Authors
- Dentali, F., Squizzato, A., Brivio, L., Appio, L., Campiotti, L., Crowther, M., Grandi, A. M., & Ageno, W.
- Affiliations
- University of Insubria (IT)
- McMaster University (CA)
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2009-05-28
- Volume
- 113
- Issue
- 22
- Pages
- 5617-5623
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2000782581
- Cited by
- 176
- References
- 60
- Citations by year
- 2026: 6 · 2025: 5 · 2024: 9 · 2023: 7 · 2022: 6 · 2021: 7 · 2020: 12 · 2019: 7 · 2018: 6 · 2017: 10 · 2016: 8 · 2015: 12 · 2014: 12 · 2013: 13 · 2012: 18
- FWCI
- 2.21
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Blood (publishedVersion)
- PubMed (publishedVersion)
- IrInSubria (University of Insubria) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Myeloproliferative Neoplasms: Diagnosis and Treatment
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Keywords
- JAK2 V617F mutation, myeloproliferative neoplasms, venous thromboembolism, splanchnic vein thrombosis, mutation detection, early diagnosis, prevalence
- MeSH terms
- Algorithms, Female, Gene Frequency, Humans, Male, Myeloproliferative Disorders, Neoplasms, Phenylalanine, Philadelphia Chromosome, Biomarkers, Tumor, Valine, Case-Control Studies, Point Mutation, Amino Acid Substitution, Janus Kinase 2, Venous Thromboembolism, Early Detection of Cancer
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
